Search 

Sachs Associates is a long established international conference company with offices in Switzerland and the UK. It runs a limited number of high profile conferences in Europe and the USA which are focused on bio-pharma, medtech, and digital health. These conferences focus on licensing and investment opportunities and all provide presenting opportunities for companies and excellent meeting facilities for all delegates to network.

Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.

BioProduction by Sekisui offers contract development and manufacturing services for the biopharmaceutical industry.  Our facility in the UK has over 40 years of large scale microbial fermentation and purification experience and are in the midst of a $19M GMP expansion. 

We offer expertise in bioprocess development, scale up and manufacturing of enzymes, plasmids, chromatography ligands and other proteins for use in biopharmaceuticals.

CDMO with expertise in manufacturing enzymes, antibody fragments, plasmids and other proteins produced through microbial fermentation.  We are currently expanding our cGMP capabilities to take on additional projects.

Silence Therapeutics is a leading RNAi company, developing highly innovative medicines with life-saving potential for patients with serious and rare diseases, based upon its proprietary mRNAi GOLD platform.


RNAi enables the targeting of virtually any disease related protein including those classed as undruggable by traditional therapeutic approaches. Our proprietary mRNAi GOLD platform enables highly specific gene silencing of any gene expressed in liver hepatocytes, opening up the potential to treat many diseases - from rare hematological disorders to widespread cardiovascular diseases. The validated and modular nature of this approach means we can move very rapidly from target identification through to IND/CTA enabling studies. Products developed using our technology are patient friendly with subcutaneous administration and infrequent dosing.

The Company is in a strong position to maximize the potential of its IP and technology through collaborations and the advancement of internal programs toward the clinic.

Pioneering medicines for crossing biological barriers. SomaServe operate the PolyNaut platform: technologies for targeted and cell specific delivery of gene therapies and protein therapeutics to the brain and other intractable regions.